Rebecca Chambers Sells 527 Shares of Veracyte, Inc. (NASDAQ:VCYT) Stock

Veracyte, Inc. (NASDAQ:VCYT) CFO Rebecca Chambers sold 527 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $43.85, for a total transaction of $23,108.95. Following the sale, the chief financial officer now directly owns 113,510 shares of the company’s stock, valued at approximately $4,977,413.50. This trade represents a 0.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Rebecca Chambers also recently made the following trade(s):

• On Tuesday, December 3rd, Rebecca Chambers sold 7,000 shares of Veracyte stock. The stock was sold at an average price of $43.23, for a total transaction of $302,610.00.

Veracyte Price Performance

NASDAQ VCYT opened at $45.20 on Thursday. The business’s 50 day moving average price is $42.53 and its 200-day moving average price is $35.94. Veracyte, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $47.32.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.16. The business had revenue of $115.86 million for the quarter, compared to analysts’ expectations of $109.81 million. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The business’s revenue was up 28.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.03) earnings per share. On average, equities research analysts expect that Veracyte, Inc. will post 0.38 earnings per share for the current year.

Hedge Funds Weigh In On Veracyte

Hedge funds have recently added to or reduced their stakes in the company. HighTower Advisors LLC bought a new stake in Veracyte in the third quarter worth about $554,000. Eventide Asset Management LLC raised its holdings in shares of Veracyte by 20.2% in the third quarter. Eventide Asset Management LLC now owns 677,883 shares of the biotechnology company’s stock worth $23,075,000 after buying an additional 113,883 shares during the period. Erste Asset Management GmbH bought a new stake in shares of Veracyte during the 3rd quarter worth approximately $574,000. Intech Investment Management LLC purchased a new position in Veracyte during the 3rd quarter valued at $723,000. Finally, Neo Ivy Capital Management bought a new position in Veracyte in the 3rd quarter valued at $820,000.

Wall Street Analyst Weigh In

Several analysts have commented on VCYT shares. UBS Group boosted their price target on shares of Veracyte from $43.00 to $46.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC increased their price target on Veracyte from $44.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Guggenheim started coverage on Veracyte in a research note on Thursday, October 10th. They issued a “buy” rating and a $40.00 price objective on the stock. StockNews.com cut Veracyte from a “buy” rating to a “hold” rating in a report on Tuesday, January 28th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $37.00 target price (down from $38.00) on shares of Veracyte in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.